Physician profile
Dwight E Lewis
NPI 1790793164
$3,039.70
in general payments reported to CMS, 2019-2025
32 companies · $949 in 2025
The $949 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $195 · 2021: $202 · 2022: $448 · 2023: $284 · 2024: $471 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.57 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.95 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $349.37 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $346.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $301.86 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $209.15 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $179.77 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.67 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $158.95 | 2019-2025 | |
| Allergan, INC. | $122.85 | 2019 | |
| Astellas Pharma US INC | $104.83 | 2024 | Veozah |
| Amgen INC. | $94.39 | 2020-2025 | Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.38 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $62.61 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $58.81 | 2020-2025 | |
| Insulet Corporation | $54.25 | 2025 | Omnipod |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $41.27 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $25.99 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $24.55 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.25 | 2025 | Rexulti |
| Dexcom, INC. | $19.94 | 2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $19.83 | 2025 | Austedo Xr |
| Abbott Laboratories | $19.70 | 2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.31 | 2025 | Xifaxan |
| Exact Sciences Corporation | $16.83 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.96 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $14.66 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.63 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $12.92 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.70 | 2020 | |
| Sanofi Pasteur INC. | $12.27 | 2019 | |
| Merck Sharp & Dohme LLC | $12.07 | 2019 | |
| Grt US Holding, INC. | $10.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.